# US 2014/0275009 A1 · Compounds useful as inhibitors of atr kinase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0275009 A1
- Document ID: US20140275009A1
- Status: Published application
- Kind: A1
- Application number: 14/098,640
- Filed: 2013-12-06
- Published: 2014-09-18
- Earliest claimed: 2013-03-15
- Assignees: Vertex Pharmaceuticals Incorporated
- Applicants: Vertex Pharmaceuticals Incorporated
- Inventors: Guy Brenchley; Jean-Damien Charrier; Chris Davis; Steven Durrant; Gorka Etxebarria I Jardi; Damien Fraysse; Juan-Miguel Jimenez; David Kay; Ronald Knegtel; Francoise Pierard; Joanne Pinder; David Shaw; Pierre-Henri Storck; John Studley; Heather Twin
- Web page: https://patentgrep.com/patent/US20140275009A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 5/1028: {using radiation sources applied onto the body}
- A61N 5/1077: {Beam delivery systems}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 453/02: containing not further condensed quinuclidine ring systems
- C07D 471/08: Bridged systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- A61N 2005/1087: {Ions; Protons}
- A61N 2005/1089: {Electrons}
- A61N 2005/109: {Neutrons}
- C12Y 207/11001: Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

## Claims

### Claim 1

A compound of formula I:
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R1 and R2 are independently selected from H; halo; —C(J1)2CN; —CN; W; or M;
J1 is independently selected from H or C1-2alkyl; or
two occurrences of J1, together with the carbon atom to which they are attached, form an optionally substituted 3-4 membered carbocyclic ring;
M is a C1-8aliphatic wherein up to three methylene units are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—, each M is optionally substituted with 0-3 occurrences of R2a;
R2a is independently selected from halo; —CF3; —CN; a C1-4aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—; or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur;
W is independently selected from a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from oxygen, nitrogen or sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from oxygen, nitrogen, or sulfur; wherein W is optionally substituted with 0-5 occurrences of JW;
JW is independently selected from —CN, halo, —CF3; a C1-4aliphatic wherein up to two methylene units are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—; or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur;
two occurrences of JW on the same atom, together with atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or
two occurrences of JW, together with W, form a 6-10 membered saturated or partially unsaturated bridged ring system;
A is independently selected from:
p is 0, 1, or 2;
R3 is independently selected from -(L)n-Q1 or T;
L and T are each independently a C1-10aliphatic chain wherein up to three methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, —S(O)z—, or —C(O)—; each L and T is independently substituted with 0-5 occurrences of JLT;
JLT is independently selected from halo, —CN, or a C1-4aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—;
n is 0 or 1;
Q1 is independently selected from a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from oxygen, nitrogen or sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from oxygen, nitrogen, or sulfur; wherein Q1 is independently substituted with 0-5 occurrences of JQ;
JQ is independently selected from halo; —CN; ═O; Q2; or a C1-8aliphatic chain wherein up to three methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—; each occurrence of JQ is optionally substituted by 0-3 occurrences of JR; or
two occurrences of JQ on the same atom, taken together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur; wherein the ring formed by two occurrences of JQ is optionally substituted with 0-3 occurrences of JX; or
two occurrences of JQ, together with Q1, form a 6-10 membered saturated or partially unsaturated bridged ring system;
Q2 is independently a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from oxygen, nitrogen, or sulfur; or a 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from oxygen, nitrogen, or sulfur;
JR is independently selected from halo; —CN; ═O; →O; Q3; or a C1-6aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—; each JR is optionally substituted with 0-3 occurrences of JP; or
two occurrences of JR on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur; wherein the ring formed by two occurrences of JR is optionally substituted with 0-3 occurrences of JX; or
two occurrences of JR, together with Q2, form a 6-10 membered saturated or partially unsaturated bridged ring system;
Q3 is a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from oxygen, nitrogen, or sulfur; a 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from oxygen, nitrogen, or sulfur;
JX is independently selected from halo or a C1-4aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—; or
JP is independently selected from halo; —CN; ═O; a C1-6aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—; or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur; each JP is optionally substituted with 0-3 occurrences of JM; or
two occurrences of JP on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or
two occurrences of JP, together with Q3, form a 6-10 membered saturated or partially unsaturated bridged ring system;
R4 is independently selected from H, halo, a C3-4 membered cycloalkyl, 3-4 membered heterocyclyl, or C1-4aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—;
JM is independently selected from halo or C1-6aliphatic;
z is 0, 1, or 2; and
R is independently selected from H or C1-4aliphatic.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The compound of claim 1, wherein R1 is fluoro.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is —CH2CN or —CH(C1-2alkyl)CN.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R1 is chloro.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R1 is H.

### Claim 7 (depends on 6)

The compound of claim 6, wherein R2 is —CF3.

### Claim 8 (depends on 6)

The compound of claim 6, wherein R2 is C1-6aliphatic wherein up to two methylene units are optionally replaced with —O—, —NR—, —C(O)—, or S.

### Claim 9 (depends on 8)

The compound of claim 8, wherein R2 is —O(C1-3alkyl)N(C1-3alkyl) or —NR(C1-3alkyl)N(C1-3alkyl).

### Claim 10 (depends on 1)

The compound of claim 1, wherein R2 is H.

### Claim 11 (depends on 1)

The compound of claim 1, wherein Ring A is:

### Claim 12 (depends on 1)

The compound of claim 1, wherein Ring A is:

### Claim 13 (depends on 1)

The compound of claim 1, wherein Ring A is:

### Claim 14 (depends on 1)

The compound of claim 1, wherein R3 is -(L)n-Q1.

### Claim 15 (depends on 14)

The compound of claim 14, wherein n is 1.

### Claim 16 (depends on 15)

The compound of claim 15, wherein L is —O—.

### Claim 17 (depends on 14)

The compound of claim 14, wherein n is 0.

### Claim 18 (depends on 14)

The compound of claim 14, wherein Q1 is independently selected from a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from oxygen, nitrogen or sulfur.

### Claim 19 (depends on 18)

The compound of claim 18, wherein Q1 is a 3-7 membered heterocyclyl or carbocyclyl.

### Claim 20 (depends on 19)

The compound of claim 19, wherein Q1 is independently selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyrrolidinyl, piperidinyl, azepanyl, pyrazolidinyl, isoxazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,3-oxazinanyl, 1,3-thiazinanyl, dihydropyridinyl, dihydroimidazolyl, 1,3-tetrahydropyrimidinyl, dihydropyrimidinyl, 1,4-diazepanyl, 1,4-oxazepanyl, 1,4-thiazepanyl, and azetidinyl.

### Claim 21 (depends on 20)

The compound of claim 20, wherein Q1 is independently selected from pyrrolidinyl, cyclopropyl, cyclohexyl, piperidinyl or piperazinyl.

### Claim 22 (depends on 18)

The compound of claim 18, wherein Q1 is a 5-6 membered aryl or heteroaryl.

### Claim 23 (depends on 22)

The compound of claim 22, wherein Q1 is independently selected from phenyl, pyridinyl, pyrazinyl, pyrimidinyl, tetrahydropyridinyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, or 1,2,4-triazolyl.

### Claim 24 (depends on 23)

The compound of claim 23, wherein Q1 is pyridinyl.

### Claim 25 (depends on 14)

The compound of claim 14, wherein Q1 is a 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 1-5 heteroatoms selected from oxygen, nitrogen, or sulfur.

### Claim 26 (depends on 25)

The compound of claim 25, wherein Q1 is independently selected from octahydropyrrolo[1,2-a]pyrazinyl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl, octahydro-1H-pyrazino[1,2-a]pyrazinyl, 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazinyl, 2,5-diazabicyclo[4.1.0]heptane, or octahydropyrazino[2,1-c][1,4]oxazinyl.

### Claim 27 (depends on 14)

The compound of claim 14, wherein JQ is C1-6aliphatic chain wherein up to three methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, or —C(O)—.

### Claim 28 (depends on 27)

The compound of claim 27, wherein JQ is independently selected from —C(O)—, C1-4alkyl, —(C0-4alkyl)NH2, —(C0-4alkyl)NH(C1-4alkyl), —(C0-4alkyl)N(C1-4alkyl)2, —(C0-4alkyl)OH, —(C0-4alkyl)O(C1-4alkyl), —C(O)OH, —C(O)O(C1-4alkyl), N(C1-4-alkyl)2, —C(O)N(C1-4alkyl)2, or —(C1-3alkyl)O(C1-2alkyl)N(C1-3alkyl)2.

### Claim 29 (depends on 28)

The compound of claim 28, wherein JQ is independently selected from —C(O)—, Cl1-4alkyl, or —(C0-4alkyl)NH2.

### Claim 30 (depends on 14)

The compound of claim 14, wherein JQ is Q2.

### Claim 31 (depends on 30)

The compound of claim 30, wherein Q2 is a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from oxygen, sulfur, or nitrogen.

### Claim 32 (depends on 31)

The compound of claim 31, wherein Q2 is independently selected from selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, tetrahydropyranyl, tetrahydrofuranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, or morpholinyl.

### Claim 33 (depends on 32)

The compound of claim 32, wherein Q2 is oxetanyl, pyrrolidinyl, tetrahydrofuranyl, or tetrahydropyranyl.

### Claim 34 (depends on 30)

The compound of claim 30, wherein Q2 is an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from oxygen, nitrogen, or sulfur.

### Claim 35 (depends on 34)

The compound of claim 34, wherein Q2 is independently selected from 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazinyl or 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazinyl.

### Claim 36 (depends on 19)

The compound of claim 19, wherein two occurrences of JQ, together with Q1, form a bridged ring system.

### Claim 37 (depends on 19)

The compound of claim 19, wherein JQ is ═O, halo, or →O.

### Claim 38 (depends on 19)

The compound of claim 19, wherein two occurrences of JQ on the same atom, taken together with the atom to which they are joined, form a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur.

### Claim 39 (depends on 38)

The compound of claim 38, wherein the ring formed by the two occurrences of JQ on the same atom, taken together with the atom to which they are joined, is selected from oxetanyl, cyclobutyl, or azetidinyl.

### Claim 40 (depends on 14)

The compound of claim 14, wherein JR is a 3-6 membered heterocyclyl having 1-3 heteroatoms selected from oxygen, nitrogen, or sulfur.

### Claim 41 (depends on 40)

The compound of claim 40, wherein JR is independently selected from oxetanyl, piperidinyl, azetidinyl, piperazinyl, pyrrolidinyl, 1,4-diazepanyl, or morpholinyl.

### Claim 42 (depends on 41)

The compound of claim 41, wherein JR is a piperazinyl.

### Claim 43 (depends on 14)

The compound of claim 14, wherein JR is independently selected from halo, ═O, —OH, C1-4alkyl, —(C0-4alkyl)N(C1-4alkyl)2, or —(C0-4alkyl)O(C1-4alkyl).

### Claim 44 (depends on 31)

The compound of claim 31, wherein two occurrences of JR on the same atom, together with the atom to which they are joined, form a 3-6 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur.

### Claim 45 (depends on 40)

The compound of claim 40, wherein JP is halo, —C1-4alkyl, or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur.

### Claim 46 (depends on 45)

The compound of claim 45, wherein JP is selected from pyrrolidinyl or oxetanyl.

### Claim 47 (depends on 1)

The compound of claim 1, wherein R3 is T.

### Claim 48 (depends on 47)

The compound of claim 47, wherein T is independently selected from —(C1-4alkyl), —(C1-4alkyl)N(C1-4alkyl)2, —(C1-3alkyl)O(C1-2alkyl)N(C1-3alkyl)2, —(C1-4alkyl)OH, —(C1-4alkyl)NH2, or —(C1-4alkyl)O(C1-4alkyl).

### Claim 49 (depends on 48)

The compound of claim 48, wherein JLT is halo or C1-3alkyl.

### Claim 50 (depends on 1)

The compound of claim 1, wherein A is independently selected from:

### Claim 51 (depends on 50)

The compound of claim 50, wherein p is 0.

### Claim 52 (depends on 50)

The compound of claim 50, wherein p is 1.

### Claim 53 (depends on 52)

The compound of claim 52, wherein R4 is independently selected from C1-4alkyl or halo.

### Claim 54 (depends on 52)

The compound of claim 52, wherein R4 is independently selected from methyl or fluoro.

### Claim 55 (depends on 50)

The compound of claim 50, wherein R3 is -(L)n-Q1.

### Claim 56 (depends on 55)

The compound of claim 55, wherein n is 0.

### Claim 57 (depends on 55)

The compound of claim 55, wherein n is 1.

### Claim 58 (depends on 57)

The compound of claim 57, wherein L is independently selected from C1-4alkyl.

### Claim 59 (depends on 55)

The compound of claim 55, wherein Q1 is phenyl.

### Claim 60 (depends on 55)

The compound of claim 55, wherein Q1 is independently selected from a 3-6 membered carbocyclyl or a 4-6 membered heterocyclyl.

### Claim 61 (depends on 60)

The compound of claim 60, wherein Q1 is independently selected from cyclopropyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyran, dihydropyran, or tetrahydropyridine.

### Claim 62 (depends on 55)

The compound of claim 55, wherein Q1 is a 5-6 membered heteroaryl.

### Claim 63 (depends on 62)

The compound of claim 62, wherein Q1 is independently selected from pyrazolyl, pyridinyl, or pyrimidinyl.

### Claim 64 (depends on 55)

The compound of claim 55, wherein JQ is independently selected from a C1-6aliphatic chain wherein up to three methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, or —C(O)—.

### Claim 65 (depends on 64)

The compound of claim 64, wherein JQ is independently selected from —C(O)—, —C(O)C1-4alkyl or C1-4alkyl.

### Claim 66 (depends on 65)

The compound of claim 65, wherein JQ is methyl.

### Claim 67 (depends on 65)

The compound of claim 65, wherein JR is independently selected from piperidinyl or piperazinyl.

### Claim 68 (depends on 67)

The compound of claim 67, wherein JP is independently selected from oxetanyl or azetidinyl.

### Claim 69 (depends on 50)

The compound of claim 50, wherein R3 is T.

### Claim 70 (depends on 69)

The compound of claim 69, wherein T is a C1-6aliphatic chain wherein up to three methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, or —C(O)—.

### Claim 71 (depends on 70)

The compound of claim 70, wherein T is —(C1-3alkyl)O(C1-3alkyl).

### Claim 72 (depends on 1)

The compound of claim 1 independently selected from:

### Claim 73 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim at position 74

74-130. (canceled)

### Claim 131 (depends on 1)

A process for preparing a compound of formula I:
comprising reacting a compound of formula 6:
under suitable conditions to form an amide bond, wherein:
J is H or Cl; and
R1, R2, and A are as defined in claim 1.

### Claim 132 (depends on 131)

The process of claim 131, further comprising the step of preparing a compound of formula 6:
by reacting a compound of formula 5:
under suitable conditions to form an activated ester.

### Claim 133 (depends on 1)

A process for preparing a compound of formula I:
comprising reacting a compound of formula 5:
under suitable conditions to form an amide bond, wherein R1, R2, and A are as defined in claim 1.

### Claim 134 (depends on 131, 132, 133)

The process of any one of claims 131-133, further comprising the step of preparing a compound of formula 5:
by reacting a compound of formula 4:
under suitable deprotection conditions.

### Claim 135 (depends on 134)

The process of claim 134, further comprising the step of preparing a compound of formula 4:
by reacting a compound of formula 3:
under suitable condensation conditions to form a pyrimidine ring.

### Claim 136 (depends on 135)

The process of claim 135, further comprising the step of preparing the compound of formula 3:
by reacting a compound of formula 2:
under suitable condensation conditions to form a pyrazole ring.

### Claim 137 (depends on 136)

The process of claim 136, further comprising the step of preparing a compound of formula 2:
by reacting a compound of formula 1:
under suitable anion condensation conditions.

### Claim 138 (depends on 1)

A process for preparing a compound of formula I:
comprising reacting a compound of formula 9:
under suitable condensation conditions to form a pyrimidine ring, wherein R1, R2, and A are as defined in claim 1.

### Claim 139 (depends on 136)

The process of claim 136, further comprising the step of preparing a compound of formula 9:
by reacting a compound of formula 8:
under suitable condensation conditions to form a pyrazole ring.

### Claim 140 (depends on 137)

The process of claim 137, further comprising the step of preparing a compound of formula 8:
by reacting a compound of formula 7:
under suitable conditions to form an amide bond.
